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The last years have seen a steady increase in our understanding of legumain biology that is driven from
two largely uncoupled research arenas, the mammalian and the plant legumain ﬁeld. Research on
legumain, which is also referred to as asparaginyl endopeptidase (AEP) or vacuolar processing enzyme
(VPE), is slivered, however. Here we summarise recent important ﬁndings and put them into a common
perspective. Legumain is usually associated with its cysteine endopeptidase activity in lysosomes where
it contributes to antigen processing for class II MHC presentation. However, newly recognized functions
disperse previously assumed boundaries with respect to their cellular compartmentalisation and enzy-
matic activities. Legumain is also found extracellularly and even translocates to the cytosol and the
nucleus, with seemingly incompatible pH and redox potential. These different milieus translate into
changes of legumain's molecular properties, including its (auto-)activation, conformational stability and
enzymatic functions. Contrasting its endopeptidase activity, legumain can develop a carboxypeptidase
activity which remains stable at neutral pH. Moreover, legumain features a peptide ligase activity, with
intriguing mechanistic peculiarities in plant and human isoforms. In pathological settings, such as cancer
or Alzheimer's disease, the proper association of legumain activities with the corresponding cellular
compartments is breached. Legumain's increasingly recognized physiological and pathological roles also
indicate future research opportunities in this vibrant ﬁeld.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Already in the early 1980s the cysteine protease legumain was
identiﬁed in the vetch seedlings and the common bean Phaseolus
vulgaris, however not classiﬁed yet [1,2]. Only three years later, a
putative 32 kDa cysteine protease was found in the trematode
Schistosoma mansoni [3]. Another two years later, in 1989, the
32 kDa protein Sm32 was conﬁrmed to be a protease [4]. The
sequence of plant legumains was then cross-conﬁrmed by the
sequence of the homologous Schistosoma enzyme [5]. In 1990
legumain was initially named as haemoglobinase in S. mansoni [6].
Later it was also referred to as endoprotease B in germinating barley
seeds [7]. Given its localization and function in plant vacuoles [5,8],
and its strict speciﬁcity for cleaving after asparagine residues [9]
legumain was named vacuolar processing enzyme (VPE) orasparaginyl endopeptidase (AEP), and these names are still used
today. In 1993 the term ‘legumain’ was introduced by Kembhavi
et al. [10], which is nowadays its most frequently used name.
Already in 1993 it was shown that legumain very likely harbours a
protease and a ligase activity [9]. Mammalian legumain was iden-
tiﬁed in 1996 as putative cysteine protease PRSC1 in humans [11]
and conﬁrmed as legumain only one year later in pig. In 2007
legumain activity was for the ﬁrst time also found in arthropods
[12]. Further names were used for legumain to emphasise speciﬁc
functions, including ACP (asparaginyl carboxypeptidase) because of
its activity as a mono-carboxy-peptidase [13], or nucellain, because
of its localization to nucellar cell walls in barley [14]. Recently the
name “butelase 1” was used for a legumain isoform from the seeds
of Clitoria ternatea [15]. While the use of the term AEP seems
justiﬁable for its brevity or if the endopeptidase activity should be
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which is consistent with its multiple and still growing functions
and in accordance with the recommendations of the Nomenclature
Committee of the IUBMB [16].
2. Classiﬁcation within the protease world
Formally, legumain was classiﬁed as a member of clan CD and
family C13 of cysteine proteases (EC 3.4.22.34) because of the
recognition of a conserved His148-Gly-spacer-Ala-Cys189 motif. This
highly conserved motif is typical for clan CD members including
caspase-1, clostripain, gingipain R, paracaspases and metacaspases
and suggests an evolutionary relationship [16e18]. Furthermore, a
highly conserved block of four hydrophobic residues precedes the
catalytic His148 and Cys189 residues. Also, a ~15% sequence ho-
mology to caspases and its strict speciﬁcity at the P1 position link
legumain to caspases, albeit with a modiﬁed preference for the P1-
residue, Asn vs. Asp.
Notably, the C13 peptidase family of legumain-like proteins
contains the Glycosylphosphatidylinositiol:protein transamidase
(Gpi8p; C13.005) [19]. Gpi8p co-localises with the rough endo-
plasmic reticulumwhere it attaches a GPI-anchor at the C-terminus
of a nascent target protein, anchoring it to the membrane [20,21].
The evolutionary relation of Gpi8p with legumain is, therefore,
reﬂected not only by their sequence homology but also mecha-
nistically by the transamidation reaction that is catalysed by Gpi8p
[22,23]. Human Gpi8p works in complex with 3 more proteins,
namely Gaa1p, Gpi16p and Gpi17p [24e26], all 4 of them being
membrane proteins [19]. In yeast 3 homologs of these proteins
(Gaa1p, Gpi8p and Gpi16p) sufﬁce to form a stable complex [27].
Gpi8p is likely found in all eukaryotes utilizing GPI anchoring. The
genes encoding the Gpi-complex are essential in yeast, illustrating
its importance.
3. Phylogenetic distribution e who has it?
Today, there is evidence for functional legumain in plants,
mammals, Blastocystis, trematodes like S. mansoni, and ticks, but
not in bacteria [19]. The so far identiﬁed and classiﬁed number of
legumain isoforms varies with the organisms. Mammals only have
1 functional legumain isoform, plus a pseudo-gene with unknown
function in humans [19]. Plants, however, have a varying number of
functional legumain isoforms, which can be subdivided into 4
subfamilies in Arabidopsis thaliana aVPEedVPE [28]. Sunﬂower
contains at least 5 AEPs [29], and in barley 7e8 isoforms have been
identiﬁed [29,30]. Also ticks have been shown to produce more
than 1 legumain isoforms. Haemaphysalis longicornis encodes 2
functionally characterized isoforms [31,32], Ixodes ricinus has 1
characterized isoform, IrAE [33], but very likely there are evenmore
functional and non-functional isoforms in ticks [34,35]. Blastocystis
ST7, an enteric protozoan parasite, produces at least 2 isoforms [36]
and in the trematodes S. mansoni, Fasciola gigantica and Opis-
thorchis viverrini 1 to 2 isoforms have been identiﬁed [4,37,38].
With the progress of sequencing technologies and whole genome
sequencing also the number of identiﬁed legumain isoforms is
expected to further increase.
4. Tissue distribution e where is it?
Mammalian legumain is most abundant in kidney and testis,
however it was shown to have a rather broad tissue distribution
[39,40]. Furthermore, legumain could be localized to different types
of antigen presenting cells (APCs), including human and murine
dendritic cells. It is relatively abundant in murine B-cell lines and
EBV-transformed B-cell lines, underscoring its immunologicalrelevance [41e43]. Legumains of blood digesting ticks are localized
to the midgut [12]. In plants, different isoforms were shown to be
expressed at different levels in different organs and different
developmental stages. Therefore, plant legumains are not solely
expressed in seeds but also in vegetative organs [28,44,45]. aVPE
and gVPE are relatively abundant in vegetative organs [45], bVPE in
reproductive organs, in particular the seed embryo [46], dVPE in
two cell layers of the seed coat at an early stage of seed develop-
ment [28].
4.1. (extra-)Cellular localization
The cellular localisation of legumain is organism dependent.
Mammalian legumain is localized mainly to the endo-lysosomal
system, plant legumains to vacuoles, nucellar cell walls and the
pericarp [14,47] and tick legumains to the acidic compartments of
gut cells (gut epithelium), but also outside the cells in the peri-
trophic matrix [12,31,48,49]. Common characteristics of those
compartments are an acidic pH and a reducing redox-potential. In
mammalian lysosomes the reducing environment is established
amongst other factors by the transition metals iron and copper
liberated upon the degradation of metalloproteins [50,51]. Acidic
pH is maintained by ATPases that pump protons into the lumen of
lysosomes. The lysosomal pH is between 6e5 and 5e4.5 in early
and late endosomes, respectively [52]. However, when lysosomes
mature, their pH can reach values as low as 3.8 [53,54]. Likewise,
the acidic compartments of tick gut cells share a gradual change in
pH along the endocytic pathway. The pH in digestive vesicles
ranges from pH 3.5 to 4.5 [55]. Interestingly, cytokines were also
shown to have an effect on lysosomal pH in humans. IL-10 raises the
pH of APC endosomes thereby attenuating protease activities, with
consequences for MHCII loading. By contrast, IL-6 was shown to
decrease the pH in endosomes [56]. Plant vacuoles are very similar
to mammalian lysosomes with respect to acidic pH and reducing
conditions. Additionally, they are relatively high in NO3
(20e70 mM) [57] and contain glutathione, which contribute to
their redox potential [58].
4.2. How do proteins get to the lysosomal/vesicular system?
Mammalian proteins are targeted to the lysosomal system
mostly via the mannose-6-phosphate receptor pathway [52,59,60].
Lysosomal cysteine cathepsins, as an example, very often harbour
an N-glycosylation site on their N-terminal propeptides that targets
them to the vesicular pathway via the mannose-6-phosphate re-
ceptor (M6PR) [61]. Under mildly acidic conditions, they dissociate
from the M6PR in the endo-lysosome. In plants proteins enter the
vesicular system from the ER. Via an N- or C-terminal or an internal
propeptide they are further translocated to vacuoles. Proteins
scheduled for secretion lack this sequence. Furthermore, plant
vacuoles are subdivided into lytic and storage vacuoles. Proteins
ending up in lytic vacuoles are transported via the Golgi complex.
Proteins destined for storage vacuoles do not necessarily need to go
via the Golgi [62].
4.3. (patho-)Physiologic localization of mammalian legumain
outside the lysosome
Primarily under pathophysiologic conditions there is evidence
for legumain also at locations outside of acidic vesicles namely
extracellularly, in the cytoplasm and in the nucleus [63e67]
(Fig. 1). While the presentation at the cell surface has also been
described for lysosomal cathepsins under pathophysiological
conditions via the mannose 6-phosphate receptor pathway [68],
the localization to the cytosol and nucleus is puzzling and
Fig. 1. Trafﬁcking of legumain in and outside the cell. Synthesized as an inactive proenzyme, legumain is targeted via the ER and Golgi to the endolysosomal system, where it gets
activated to the asparaginyl-speciﬁc endopeptidase (AEP). Additionally it might be secreted extracellularly directly via the Golgi (dark blue path) or indirectly via the endosomal
system (light blue path). Likewise, extracellular legumain may re-enter the cell via endocytosis (green path) or directly via translocation to the cytosol (dark purple path), e.g. under
cancer conditions. Additionally, under pathophysiologic conditions like Alzheimer's disease where the lysosome is altered, legumain may enter the cytosol directly from a leaky
lysosome. Once exposed to the cytosol, legumain may then enter the nucleus (light purple path).
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main at these “non-canonical” compartments are poorly deﬁned
and often related to pathological situations, such as cancer or
Alzheimer's disease [66,69e71]. Nuclear localization is not limited
to the human system, but was also reported in plants with a po-
tential role as transcription factor [72]. The nuclear localization
appears consistent with a potential bipartite nuclear localization
sequence (KRK289, KRK318) [73] e but only if the protein is exposed
to the cytosol [74].4.4. How to exit the endo-lysosome?
It is well established that prolegumain is initially located to
compartments like endoplasmic reticulum and Golgi where it is
routed to the endosome before it becomes activated in the lyso-
some (Fig. 1). Likewise, legumain has been found at the cell surface,
albeit limited to the microenvironments of several tumours [75].
However, it is less clear, and challenging current dogma, how it can
translocate to its destinations in the cytosol and in the nucleus
[74,76].
These translocations are indeed not fully understood and puz-
zling. Nonetheless, such non-canonical trafﬁcking is not without
precedence. Recently, nuclear and cytosolic translocation of
secreted MMP-12 was documented by an array of functional and
immune-ﬂuorescent confocal microscopy data [77]; similar trans-
locations were also reported for MMP-14 [78] and, more indirect,
for MMP-7 [79].
Several hypothetical legumain routes could possibly account for
the cytosolic and nucleic localization of legumain, including
(i) cytosolic expression; an analogous situation has been
described, for example, for the lysosomal protease cathepsin
L when expressed as a splice variant lacking the N-terminal
signal peptide [80]. However, such a splice form has not been
reported for legumain and appears particularly unlikely
because the glycosylation was found necessary for the sta-
bility of human legumain [81]. Therefore, we excludecytosolic expression but rather postulate that legumain must
be routed through the ER and Golgi to obtain its required
post-translational modiﬁcations;
(ii) translocation from the cell surface into the cytosol. In this
scenario, legumain should be fully post-translationally
modiﬁed, possibly but not necessarily including autocata-
lytic activation (Fig. 2). Legumain oscillates between the
endo-lysosomal compartment and the secretory pathway
[82], explaining why its activation state can vary (Fig. 1). The
cell surface-to-cytosol translocation would resemble that of
the well documented translocation of MMP-12 into virus-
infected cells [83]. Legumain was found on the cell-surface
mostly in the context of tumours, in particular of tumour-
associated macrophages where the local pH is acidic
enough to maintain an active conformation [67,70,84e89].
Therefore, the cell surface to cytosol translocation appears a
sensible scenario in the microenvironment of tumours.
Intriguingly, nuclear localization of legumainwas reported in
tumours in agreement with the bipartite nuclear localization
sequence (NLS). The two motifs (KRK289, KRK318) are sepa-
rated by 26 amino acids, whereas standard separation would
be 10e12 amino acids [73]. A single KRK motif may be suf-
ﬁcient for nuclear localization as exempliﬁed by the
apoptotic signalling adapter molecule FADD. FADD was also
found to localize to the nucleus with a single KRK35-motif, as
demonstrated by mutagenesis [90]. In legumain the motif is
partly located on the activation peptide with the b cleavage
site at Asn323-Asp324. The active, b-cleaved form would
allow the KRK318 motif to reorganize into spatial proximity to
KRK289, thus mimicking a standard bi-partite NLS [73]. This
scenario implicitly assumes that the microenvironment of
the tumour contributes to a partial perforation of the cyto-
solic membrane, the exact mechanism being unclear.
Notably, virus-infected cells (as in MMP-12 [83]) and tumour
cells share a common immune status in presenting peptide-
MHC I complexes at their cell surface.
(iii) translocation from the endo-lysosome to the cytosol.
Depending on the maturation/acidiﬁcation of the endo-
Fig. 2. Legumain stability, activation, activities, and their regulation. A, In a simple picture prolegumain is stable at neutral pH and can be activated via pH shift to the active
endopeptidase (AEP). AEP is irreversibly destabilized at near neutral pH. B, In a more detailed picture the activation, stability, speciﬁcity and activity of different legumain variants is
controlled by different interaction partners. The pH-induced (electrostatic) activation is accelerated by glycosaminoglycans (GAGs), triggering autocatalytic activation at pH ~5.5 and
below. Alternatively, prolegumain can be proteolytically activated to the asparaginyl-speciﬁc carboxypeptidase (ACP) by selective removal of the activation peptide (dark blue). AEP
can be generated from ACP via electrostatic release of the Legumain Stabilization and Activity Modulation (LSAM) domain at acidic pH. Activated AEP is stable at pH  6 and
irreversibly conformationally inactivated at neutral pH values. Analogous to the LSAM domain, cystatins act as direct and reversible conformational stabilisers of AEP at neutral pH.
Active enzyme can be regenerated from a cystatin-AEP complex at pH < 4. Legumain can be allosterically stabilized either by binding to the integrin aVb3 via the RGD120 motif or by
ternary complex formation with TRAF6 and HSP90a. As an additional dimension of complexity, legumain protease and ligase activities are pH dependent, with the ligase dominating
at neutral pH and the protease at acidic pH.
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zymogen (full-length) form (Fig. 1). Indeed, cytosolic legu-
main has been reported as zymogen [63], but also in its fully
activated form [66,69e71]. The endo/lysosome-to-cytosol
translocation was reported in pathological situations, such
as in cancer and Alzheimer's disease [63,69], oxidative stress
and necrotic/apoptotic cell death [20,91]. Recent literature
provides further evidence about the dynamics of the lyso-
some, e.g., in the context of autophagic lysosome reforma-
tion. This complexity is exempliﬁed by the conversion of
vesicular to tubular efﬂux from the lysosome [92e94].
Additional circumstantial evidence relates to the neuronal
acidosis in Alzheimer's disease which appears linked withlysosomal biogenesis and vacuolar ATPase activity [95e97].
Moreover, lysosomal membrane permeability in Alzheimer's
disease was reported to be altered in Alzheimer patients
[98,99] and likely affected by lysosomal dysfunction
[100,101]. Therefore, it may seem plausible that legumain
may percolate from the lysosome to the cytosol.4.5. How does legumain survive at near neutral pH in the cytosol,
nucleus or at the cell surface?
While legumain is stable in its zymogen form at neutral pH,
the asparaginyl endopeptidase activity is rapidly and irreversibly
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from conformational unfolding due to the high density of acidic
amino acids, which are partially protonated at acidic pH but are
negatively charged and electrostatically repulsive at neutral pH
[13]. Adding to the cell-biological conundrum discussed in the
previous paragraph, the existence of active legumain outside the
endo-lysosomal compartment appears therefore also critical from
a protein conformational aspect. This paradox can be reconciled
by several considerations. Firstly, in the pathophysiological set-
tings of cancer and Alzheimer's disease, the relevant environ-
ments tend to be slightly acidiﬁed [84,95,103,104]. Secondly, only
uncomplexed, fully activated legumain is destabilized at neutral
pH. Several complexes such as integrin aVb3, and probably b1
integrins [105], present at the cell surface, have been shown
to stabilize activated legumain (Fig. 2B) [13,88]; likewise the
complex formation with cystatin inhibitors stabilizes activated
legumain, thereby counterintuitively acting as legumain agonists
at neutral pH [106]. Thirdly, when legumain is proteolytically
activated at pH ~5.5e6.5, the C-terminal propeptide (LSAM)
remains bound to the catalytic domain, resulting in a mono-
carboxypeptidase activity that is stable at near neutral pH [13].
Fourthly, post-translational modiﬁcations can stabilize legumain
as has been illustrated by its Lys63-linked ubiquitination by the
E3 ligase TRAF6. The ubiquitination further resulted in ternary
complex formation with the heat shock protein HSP90a, which
increased the intracellular legumain stability and secretion [63].
Legumain was ubiquitinated on its activation peptide at Lys318,
preceding the auto-cleavage site at Asn323. The modiﬁcation site
explains why ubiquitination occurred only with pro-legumain
and why ubiquitination sterically prevented auto-activation.
However, the ubiquitination could be reverted by the deubiqui-
tinase USP17 [63].
Taken together, the existence of active legumain at near neutral
pHmilieus of the cytosol, nucleus or at the cell surface is plausible if
stabilized by intra- or intermolecular complexes.5. Physiological functions
5.1. Digestion
Legumains have different functions that are mostly, but not
exclusively, related to its protease activity. Their functions are or-
ganism speciﬁc and partly adapted to the host. Tick legumain, for
example, predominantly functions as a haemoglobinase. When
ticks suck up blood, the haemoglobin that is contained in the blood
crystallizes in the gut lumen. These haemoglobin crystals are then
taken up by gut epithelial cells via receptor-mediated endocytosis
[107]. The vesicles containing host haemoglobin consequently fuse
with lysosomes containing the active haemoglobinases. There
haemoglobin is digested to peptides and free amino acids [35].
Legumain facilitates haemoglobin digestion not only directly by
processing haemoglobin but also by activating other proteases.
Recent genetic analysis also showed that there might be more yet
unknown legumain isoforms with different functions, potentially
also organized in a cascade-like manner [34]. Likewise, Schistosome
legumain is also a key mediator of haemoglobin degradation [108].
Plant legumains are key enzymes in the processing and activation
of seed storage proteins during seed maturation [109e113]. Arabi-
dopsis mutants lacking VPE genes (a, b, g) accumulated precursor
proteins in seeds, further illustrating the importance of this class of
enzyme in seed maturation. Interestingly, bVPE is especially
important, because it can compensate missing a and g genes [113].
Consequently, vegetative VPEs (a and g) are not a prerequisite for
precursor protein processing as long as bVPE is present.5.2. Immunity
In mammals, legumain plays important roles in the immune
system. In particular, legumain is involved in processing self and
foreign proteins for presentation on the MHCII complex. Thereby it
is involved both in generating tolerance by destructing self-
proteins and in mounting immune responses towards foreign an-
tigens by their processing [114e117]. Legumain is thus catalysing
the generation as well as the destruction of T-cell epitopes [118]. A
prominent example for the deleterious effects with peptide
destruction is given by legumain's association with multiple scle-
rosis [43].
5.3. Antimicrobial activity
Also in plants legumains are important components of the im-
mune system. Prominent examples include the generation of cyclic
peptides that are important for plants' defence against pathogens
[119]. The immunological relevance of such cyclic peptides can be
illustrated by Kalata B1 from the African plant Oldenlandia afﬁnis
that has proven antimicrobial and insecticidal activities, amongst
others [120,121]. Furthermore, it is the active component that is
used in native African medicine to accelerate child birth [122].
5.4. (Immune) signalling
Besides its immunological role in antigen processing and
cyclotide generation, legumain is also an important factor in im-
mune signalling. Legumain was shown to proteolytically activate
TLRs, receptors of the innate immune system [123,124], although
cathepsins seem to be sufﬁcient to carry out TLR processing in the
absence of legumain [125]. Likewise, processing of endo-lysosomal
cysteine proteases by legumain was proven in vitro and in vivo
which again modulates the downstream immune response [126].
Moreover, legumain can initiate the removal of the invariant chain
chaperone of MHCII, thereby not only critically inﬂuencing peptide
generation but also MHCII activation [127]. Signalling is not
restricted to the immune system but also includes the activation of
other proteases at the cell surface [128].
5.5. Apoptosis
Plant legumains are discussed as main mediators of pro-
grammed cell death in plants since they perform caspase-like ac-
tivities/speciﬁcities; with several plant legumain isoforms present,
they could potentially resemble caspase activation cascades. Along
that line, legumains mediate the response against pathogens in
tobacco [129], in the chemical-induced apoptosis in tomato [130],
in nitric oxide-induced cell death in Arabidopsis [131] and more
recently, in virus induced hypersensitive cell death [132]. For a
detailed review on legumain in plant cell death see Ref. [133].
Furthermore, human legumain was shown to be involved in
neuronal apoptosis by degrading a DNase inhibitor during excito-
neurotoxicity [134].
5.6. Transcription factor
While most legumain literature reports on its protease activity,
there is also literature reporting protease-independent functions of
legumain, including its transcription factor activity. A legumain
from tomato leaveswas shown via chromatin immunoprecipitation
to bind to the promoter of ACS (1-aminocyclopropane-1-1carbox-
ylic acid synthase) and thereby induce gene expression [72]. ACS is
inducing ethylene biosynthesis, which is a hormone inﬂuencing
plant growth, development and defence response. Likewise, human
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pathophysiologic conditions [66]. It is tempting to speculate that
there it might also act as a regulator of gene expression, i.e. as a
transcription factor [72]. Structural analysis would suggest an
electrostatic complementarity of the negatively charged DNA
phosphate backbone to the basic C-terminal LSAM domain, not to
the catalytic domain [13].
Intriguingly, an analogous transcription factor activity has been
demonstrated for MMP-12 which is secreted but was found to
translocate to the nucleus of virus-infected cells, exhibiting an
antiviral effect [83].
5.7. Osteoclast remodelling
Legumain was also found in the inhibition of osteoclast forma-
tion and thus to inhibit bone resorption [135e137]. Interestingly,
the environment of osteoclasts as well as their cytosol is slightly
acidic, consistent with legumain being in an active state [138e140].
However, the osteoclast inhibitory function was mapped to the C-
terminal prodomain and is correspondingly independent of its
protease activity. To emphasize its role in bone remodelling, legu-
main was synonymously termed osteoclast inhibitory peptide 2
[136].
5.8. Legumain deﬁcient mice
Legumain knock out mice have been constructed by different
groups and proved to be healthy with some minor phenotypes,
when unchallenged [123,124,126,141,142]. Legumain knock out
mice showed slower antigen processing (TTCF); the initial T-cell
response is faster in wild-type mice. However, the difference to the
ﬁnal anti-tetanus response was only little [116]. Moreover, the mice
had a normal phenotype, were viable and healthy but did not gain
weight at the same rate as wild-type littermates [116]. Further-
more, Chan and colleagues found that legumain-deﬁcient mice
accumulated procathepsins in the kidney, which is typical for
lysosomal disorders [141]. Additionally, the mice showed symp-
toms typical for the hemophagocytic syndrome.
6. Domain architecture e how does legumain look like?
Like the lysosomal cathepsins, legumain is synthesized as an
inactive proenzyme that needs to undergo pH dependent auto-
catalytic activation to release the active endopeptidase [39,143].
Essentially, human prolegumain starts with a signal peptide (Met1-
Ala17) that is released during trafﬁcking, followed by a short 8
amino acid N-terminal propeptide (Val18-Asp25), the cysteine
protease domain (Gly26-Asn323) and a C-terminal prodomain
(Asp324-Tyr433) (Figs. 3 and 4A) [13,39]. The cysteine protease
domain has a caspase-like overall structure and harbours the cat-
alytic triad (Cys189-His148-Asn42) and, depending on the organ-
ism, a varying number of N-glycosylation sites. Human legumain
harbours 4 N-glycosylation sites resulting in a molecular weight of
~56 kDa of the fully glycosylated proenzyme [13,18]. The C-terminal
prodomain adopts a death-domain-like architecture that is addi-
tionally stabilized by 2 disulﬁdes [13]. Furthermore, the catalytic
domain harbours an RGD motif that proved to be important for
interaction with integrin aVb3 [88]. Recently a (reversible) ubiq-
uitination site (Lys318) and TRAF6 binding site have been identiﬁed
with consequences in breast cancer [63]. While prolegumain is
stable at neutral pH, active uncomplexed legumain is destabilized
at pH > 6.0.
Overall, the catalytic domain is highly conserved throughout all
kingdoms, while the C-terminal prodomain is less well conserved
(Fig. 3). However, structural elements like the catalytic residues anddisulﬁdes are highly conserved. Glycosylation sites, the RGD-motif,
the TRAF6-binding sequence, signal peptides and the exact
sequence and position of autocatalytic processing sites is varying
throughout different organisms and likely presents a means to
adapt the enzyme to the speciﬁc needs of the host.6.1. Recombinant access
The gene encoding human legumain is located on chromosome
14 at the locus14q32.12. Since prolegumain harbours several
posttranslational modiﬁcations like N-linked glycosylation sites,
disulﬁdes and autocatalytic processing sites, recombinant expres-
sion of the enzyme proved to be challenging. However, meanwhile
the successful production in different expression systems has been
reported; for a detailed list see Table 1.With some exceptions it was
mostly eukaryotic systems including insect cells, yeast, HEK, CHO
and LEXSY that proved to be successful. However, recently the
expression of different plant isoforms as soluble proteins in the
E. coli Shufﬂe strain was reported [144]. If the proenzyme was
produced recombinantly, subsequent puriﬁcation proceeded
mostly via a His-tag and Ni-afﬁnity puriﬁcation.6.2. Crystal structures of legumain
Crystal structures of prolegumain and the enzymatically active
endopeptidase domain have been determined recently for human,
mouse and Chinese hamster legumains [13,145,146]. For repre-
sentative pdb entries see 4aw9, 4fgu, 4noj, 4nok, 4d3x. The crystal
structures revealed that prolegumain comprises of the caspase-like
AEP domain and a C-terminal prodomain positioned on top of the
active site (Fig. 4B). The prodomain can be further segmented into a
latency conferring activation peptide (AP) and an LSAM (Legumain
Stabilization and Activity Modulation) domain. Substrate access in
prolegumain is prohibited by the AP on the non-primed and S10and
by the LSAM domain on the primed substrate interaction sites,
explaining why prolegumain is enzymatically inactive. The LSAM
domain has a death domain (DD)-like fold, albeit with different
connectivity of the DD-helices, and is additionally stabilized by two
disulﬁdes (Fig. 4B, C).6.3. The catalytic-domain e legumain is protease and ligase
Legumain's functions in digestion, antigen processing, signalling
via processing/activation can be attributed mainly to its protease
and ligase activities. Therefore, there can be no doubt that the
catalytic caspase-domain is the molecule responsible for fulﬁlling
these functions, although the LSAM domain modulates the pepti-
dase and possibly also the ligase function, as discussed below.6.3.1. Protease substrates
Meanwhile a huge number of legumain protease substrates have
been identiﬁed in different organisms. For a detailed list including
references please refer to Table 2. Essentially, protein substrates
include prolegumain itself, (auto)antigens like the myelin basic
protein (MBP) or the tetanus toxin C-terminal fragment (TTCF),
other lysosomal proteases like cathepsins B, H and L and their
cystatin inhibitors; immune-related proteins like innate Toll-like
receptors TLR9/7 and the invariant chain chaperone Ii; seed stor-
age proteins, proforms of cyclic inhibitors, haemoglobin seem
speciﬁc to plants; in Alzheimer's disease the protein phosphatase 2
inhibitor SET and the tau protein. All these substrates share an
asparagine or aspartic acid at P1 position.
Fig. 3. The legumain sequence space includes GPI-transamidase and caspases. A sequence alignment of human (Q99538), mouse (O89017), chinese hamster ovary (CHO, G3I1H5)
and schistosome legumain (Q9NFY9), Haemaphysalis longicornis legumain isoform 1 (tick_1st; A4PF00) and isoform 2 (tick_2nd A9CQC1), A. thaliana aVPE (P49047), bVPE
(Q39044), gVPE (Q39119), dVPE (Q9LJX8) and jack bean legumain (P49046), human GPI-transamidase (Q92643) and human caspase-1 (P29466) was prepared using ClustalW [265]
and modiﬁed with Aline [266]. Autocatalytic processing sites are indicated with arrows, catalytic residues with red stars, glycosylation sites with green triangles, S1-speciﬁcity
residues with blue diamonds, the double arginine-motif (Arg342, Arg403) with light blue diamonds, the RGD120 motif is shaded in yellow, the TRAF6-binding site in purple
(A210NPRESSY217), the ubiquitination site Lys318 is indicated by a purple circle and the KRK289eKRK318 motifs, constituting a potential nuclear localization signal, are labelled with a
blue box. The sequence numbering corresponds to human legumain. Secondary structure elements are indicated based on the crystal structure of human prolegumain (pdb entry
4fgu), whereby green elements correspond to the catalytic domain, blue elements to the activation peptide and orange elements to the LSAM (Legumain Stabilization and Activity
Modulation) domain.
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Although legumain is mostly referred to its hydrolytic activity,
some of its functions are most likely independent from its protease
activity, including its roles as transcription factor [72] or in osteoclast
remodelling. The latter activity was mapped to its C-terminal pro-
domain [136]. Also, some of its reported (extra)cellular locations areincompatible with the pH-stability requirements of the active pro-
tease. Therefore, it is more likely that under such conditions either
full-length prolegumain or a stabilized complex of the catalytic
domain with an unspeciﬁed partner is present at those locations.
Furthermore, the recognition of a death-domain like architecture
within the prodomain provokes the speculation whether the LSAM
domain is mediating proteineprotein interactions, typical for the
Fig. 4. Domain architecture of legumain. A, 1D-diagram of human prolegumain. Red: signal peptide (SP), light green: N-terminal fragment (NTF), dark green: catalytic domain, blue:
activation peptide (AP; KRK289eN323), orange: Legumain Stabilization and Activity Modulation (LSAM; D324eY433) domain. (Autocatalytic) processing sites are labelled by arrows,
catalytic residues by red stars, S1-speciﬁcity residues by blue diamonds, and the RGD120 motif by a purple triangle. Disulﬁde bridges on the LSAM domain are indicated. B, Crystal
structure of human prolegumain (pdb entry 4fgu). The caspase-like catalytic domain is shown in green, the AP in blue and the LSAM domain in orange. The active site is labelled by
the catalytic Cys189 and the C-terminal processing sites KRK289 and N323 are shown in sticks. The KRK289eKRK318 motif on the AP represents a potential bipartite nuclear local-
ization signal. Furthermore, legumain may get ubiquitinated at Lys318. C, Topology diagram of prolegumain. The catalytic domain is shown in green, the AP in blue and the LSAM
domain in orange. Red stars: catalytic residues, blue diamonds: S1-speciﬁcity residues.
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their N-terminus CARDs (caspase recruitment domain) and DEDs
(death effector domain). These modules form, together with the DDs
(death domains) and the PYDs (pyrin domains), the death-fold su-
perfamily of homotypic interactionmotifs [147]. Death domains play
pivotal roles in apoptosis, necrosis, inﬂammation and immunity by
mediating the assembly of oligomeric signalling complexes like the
apoptosome or the inﬂammasome [148,149]. Death domain in-
teractions do generally not cross the boundaries of a subfamily [147].
The death-fold is characterized by a bundle of typically 6 antiparallel
a-helices forming a Greek key topology [150]. They interact mostly
via three types of asymmetric interactions [21,151]. The six so far
identiﬁed interaction patches are non-overlapping, therefore each
module can in theory bind up to six partners [147]. Oligomeric
complexes have been identiﬁed for DDs [152,153]. CARDs, PYDs and
DEDs have only been found in dimeric complexes [21,154,155].
Therefore it is tempting to speculate, whether similar complexes
exist for (pro)legumain, the asparaginyl-speciﬁc carboxypeptidase
or the isolated LSAM domain.7. Activation of legumain
7.1. Activation to asparagine-speciﬁc endopeptidase (AEP)
While prolegumain is synthesized as inactive zymogen (56 kDa
in mammals), an acidic pH shift triggers autocatalytic processing atboth termini, resulting in 47 kDa and 46 kDa intermediate legumain
species (Fig. 5A) [102,143]. The C-terminal processing site in
mammals was assigned to Asn323, N-terminal processing occurs
after Asp21 and Asp25 [102,143,156]. C-terminal processing is
already observed at pH 5.5 whereas processing after the N-terminal
aspartic acid residues is restricted to pH  4.5. While processing
after the Asn323 residue proved to be critical to generate peptidase
activity, N-terminal cleavage is not essential for activation [81].
Additionally, another auto-cleavage site was identiﬁed in the hu-
man variant after Asp303-309 residues [81]. In vivo, an additional
C-terminal in trans trimming of 46 kDa legumain is observed,
performed by a different protease resulting in a 36 kDa legumain
variant. However, the identity of the protease and the exact
cleavage site remain unclear. Indirect evidence hints at KRK289 as
the additional processing site, which might be performed by an
enzyme with trypsin-like speciﬁcity like prohormone convertases,
e.g. PC2 [13,16]. Interestingly, the enzymatic activity of the 36 kDa
and the 46 kDa species towards a peptidic substrate is virtually
identical [102]. Similarly, Asp303-309 processed legumain does not
differ in activity [81]. Instead, this processing may affect legumain's
ubiquitination by TRAF6 which occurs at Lys318 [157]; additionally,
the Asp303/309 cleavage will likely inﬂuence its nuclear localiza-
tion, as it disrupts the bipartite nuclear localization motif KRK289-
X26-KRK318.
Upon auto-activation the pH-stability proﬁle of legumain is
changing dramatically. While prolegumain is stable at near
Table 1
Recombinant expression systems.
Organism Isoform/mutants Reference
Pichia pastoris
Sugar cane [267]
Barley HvLeg-2, HvLeg-4 [30]
Ixodes ricinus [12]
Branchiostoma belcheri [235]
Schistosoma mansoni C189N [160,175]
HEK293
Human N323A [102,268]
Mouse H45A, H148A, C189S [40]
Insect cells
Mouse [145]
Human [145]
Arabidopsis thaliana gVPE [159]
LEXSY
Human E190K [81]
CHO
Chinese hamster ovary [146]
Human [143]
E. coli
Blastocystis GST-fusion [269]
Castor bean [5]
Sunﬂower HaAEP1 [144]
Jack bean CeAEP1 [144]
Arabidopsis AtAEP2 [144]
Castor bean RcAEP1 [144]
E. coli refolding
Haemaphysalis longicornis HlLgm2 [31]
Schistosoma mansoni [270]
E. Dall, H. Brandstetter / Biochimie 122 (2016) 126e150 135neutral pH, auto-catalytically activated legumain is stable at
acidic pH, as found in the endo-lysosomal system, but destabi-
lized at pH > 6.0.Table 2
Legumain substrates.
Protease/ligase substrate Protease su
Mammals
Annexin A2
Cathepsin B, H, L, S
Progelatinase A
Myelin basic protein (MBP)
(Pro)legumain AsneAsp
TTCF (Tetanus toxin C-terminal fragment)
TLR 7/9
Invariant chain chaperone (Ii)
BetV1
Fibronectin
Acetoacetyl-CoA synthetase
SET
Tau
Cystatin C, E AsneAsp/S
TDP-43 (TAR DNA-binding protein 43)
Tick, schistosoma
Haemoglobin
Schistosoma cathepsin B
BSA
Prolegumain
Plant
Globulin
11S/12S proglobulin
Albumins
Prolegumain
Glutelin
Gliadin
SH-EP (Serine protease inhibitor precursor)
Proconcanavalin A AsneGlu
PawS1 (‘pro-SFTI-1’) AsxeXxx
Kalata-type cyclic peptides (e.g. Oak1 ¼ precursor of kalata B1) AsneGly/S
Cyclic knottins AsxeXxxSimilar to mammalian legumain, plant, Schistosome and tick
legumains are also activated via autoproteolytic processing at acidic
pH [12,158e160].
7.2. Activation to ACP
The recently determined crystal structures of prolegumain and
the enzymatically active endopeptidase revealed a two-domain
organization of prolegumain with a caspase-like AEP (peptidase)
domain and a C-terminal prodomain positioned on top of the
enzyme (Fig. 4B) [13,145,146]. The prodomain can be further sub-
divided into a latency conferring activation peptide (AP) and an
LSAM (Legumain Stabilization and Activity Modulation) domain.
The AP blocks access on the non-primed and S10 site, and the LSAM
domain on the primed substrate binding sites, explaining why
prolegumain is inactive. Besides blocking substrate access, the
LSAM domain serves as an electrostatic stabilizer of the AEP
domain at neutral pH by triggering an electrostatically encoded
stability switch (ESS) localized near the AEP active site. Selective
proteolytic removal of the AP at (near) neutral pH converts prole-
gumain into an asparaginyl-speciﬁc mono-carboxypeptidase (ACP;
Fig. 5A, B) [13]. The standard auto-catalytic cleavage after Asn323
(b-site) clips the C-terminal end of the AP and renders the active
site at least partially available. An additional cleavage after a KRK289
site (a-site) at the N-terminal end of the AP is needed for its release.
The latter cleavage is most likely performed by an enzyme with
trypsin-like speciﬁcity like PC-2. Contrasting the standard activa-
tion at low pH, the LSAMdomain remains electrostatically bound to
the AEP domain and is thereby stabilizing it at neutral pH, similar as
observed for prolegumain. The LSAM domain not only conforma-
tionally stabilizes the peptidase at neutral pH, but also provides a
double arginine motif that is characteristic for carboxypeptidasesbstrate (P1eP10) Ligase product(P1eP10) Reference
[233]
[79,126]
[128]
[43]
AsneAsp [81,102,143,156]
[115]
[123,124]
[127]
[271]
[272]
[273]
[134]
[71]
er AsneAsp/Ser [106]
[254]
[35,108]
[274]
[49]
[12,160]
[275]
[112,113]
[113,276]
[158,159,277]
[111,278]
[279,280]
AsneSer [9,205]
AspeGly [206]
er/His AsneGly [122,207]
AspeGly [208]
Fig. 5. Activation of legumain to the asparaginyl-speciﬁc endopeptidase (AEP) or carboxypeptidase (ACP). A, Inactive prolegumain is synthesized at neutral pH and undergoes
autocatalytic processing at the C-terminal Asn323 (pH  5.5) and D303/309 (pH  4.0) sites and N-terminally after Asp21 and Asp25. Another in trans processing occurs after the
KRK289 motif by an unknown protease. While N-terminal processing is not essential for enzyme activation, C-terminal processing renders the non-primed substrate binding sites
accessible. The release of the activation peptide (blue) generates ACP whereas the release of the Legumain Stabilization and Activity Modulation (LSAM) domain is obligatory to gain
full AEP activity. B, Proteolytic and electrostatic activation of legumain. At pH  6 legumain can be activated to an Asn-speciﬁc mono-carboxypeptidase (ACP) by proteolytic release
of the activation peptide (AP; proteolytic activation). Shifting pH to < 5 leads to the electrostatic removal of the LSAM domain and releases the active endopeptidase (electrostatic
activation). C, Zoom-in view on the ACP active site with a modelled substrate (Ac-YVADjA; blue sticks). The substrate was modelled based on the Ac-YVAD-chloromethylketone
complex structure (pdb entry 4aw9). The double-arginine-motif (Arg342, Arg403) is shown in orange sticks. D, Zoom-in view on the AEP active site. Catalytic residues are
shown in green sticks, S1-speciﬁcity resides in blue (Arg44, His45) and red (Glu187, Asp231) sticks, and Glu190 in yellow sticks.
E. Dall, H. Brandstetter / Biochimie 122 (2016) 126e150136(Fig. 5B, C) [161]. The notion that legumain can develop endo- and
exopeptidase activities in a pH-dependent manner is similar as
observed in cathepsin B. Cathepsin B can develop endo- and
exopeptidase activities depending on the conformation of an
occluding loop [162]. At acidic pH (in the lysosome), cathepsin B
acts as a carboxypeptidase, whereas at near neutral pH (early en-
dosome; extracellularly), it acts as an endopeptidase. The pH-
dependence of the legumain AEP and ACP activities is differing,
with the carboxypeptidase activity present at near neutral pH and
the endopeptidase activity dominating at acidic pH. The distinct
activation states of legumain differ in both their biophysical andenzymatic properties and thus help to reconcile its partly con-
ﬂicting moonlighting activities and localizations.
7.3. Catalytic mechanism of legumain protease activities (AEP/ACP)
A key feature of carboxypeptidases is a positively charged an-
chor to electrostatically grab a substrate's C-terminus [161]. Legu-
main harbours the double arginine motif Arg342 and Arg403,
derived from the LSAM helices DDa2 and DDa4. While the double
arginine motif is important for legumain ACP activity only, the
active site residues Cys189, His148 and Asn42 are essential for both
Fig. 6. Crystal structure of the asparaginyl-speciﬁc endopeptidase (AEP). The crystal
structure of human legumain activated at pH 4.0 is shown as a green cartoon (pdb
entry 4awb). The active site is labelled by the covalent Z-Ala-Ala-AzaAsn-chlor-
omethylketone inhibitor (orange sticks). Catalytic residues and the RGD120 motif are
shown as sticks.
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ranged similar to the conformation found in caspases, and likewise
the deprotonation of the catalytic Cys189 occurs spontaneously
(i.e., not triggered by a catalytic base) and is dependent on the local
pKa. The role of the catalytic His148 most likely is, together with
the amides nitrogens of Cys189 and Gly147, to complete the oxy-
anion pocket for the substrate's P1 residue; additionally, it may
serve as catalytic acid for the leaving P10 residue and thereby
facilitate the rupture of the scissile peptide bond. The side chain of
Asn42 is located at a position similar to the carbonyl oxygen at
position c177 in caspases. Although the exact role of Asn42 in
catalysis is unclear, it most likely orients His148 and thus assists in
polarizing and activating the substrate. The same might be true for
the carbonyl oxygen 177 in caspases [163], paracaspases [164,165]
and metacaspases [166].
7.4. Comparison of legumain with caspases and cathepsins
Legumain was classiﬁed as a member of clan CD, the caspase-
like enzymes, by its sequential and structural relationship, as
testiﬁed by a ~15% sequence homology and a highly conserved
sequence motif surrounding the active site residues (Fig. 3). These
highly conserved motifs suggest an evolutionary relationship
[16e18]. Also, its strict speciﬁcity at the P1 position links it to
caspases, albeit different in the nature of the preferred P1-residue.
However, its location to the endo-lysosomal system, its pH
dependent autoproteolytic activation, its pH stability proﬁle, and its
physiologic functions rather link it to cathepsins (clan CA). Like-
wise, it is inhibited by several members of the cystatin superfamily
providing a further relation to cathepsins. But these similarities are
only superﬁcial and not reﬂected by a detectable sequence ho-
mology between legumain and cathepsins [39]. Essentially, legu-
main resembles a caspase in cathepsin's clothing. Indeed, cystatins
are inhibiting legumain via a structurally distinct reactive centre
loop located on the opposite to its papain/cathepsin-reactive loops
[167,168]. Therefore, the interaction of cystatins with legumain is
not indicative for a structural similarity. Consistently, legumain is
insensitive to E-64, a broad spectrum epoxy inhibitor of papain-like
proteases [39,167]. AEP's catalytic domain has a caspase-like fold
and also the interaction with a substrate is very much like in cas-
pases (Figs. 6 and 5D). Although, the core of secondary structure
elements is caspase-like, there exist somemajor differences. Firstly,
there are four extra helices. One is separated from helix a2 via the
RGD motif (aI), aII is replacing the intersubunit linker connecting
what is known as large and small subunit from caspases and there
are two extra helices at the C-terminus (aIII and aIV) (Fig. 4C).
Secondly, the loop regions (L2eL4), which are important for cas-
pase activation, are different. There is an enormous extra loop
starting after b2 spanning from Met70 to Thr109. This legumain
speciﬁc insertion-loop is well conserved among all kingdoms,
suggesting a speciﬁc function (Fig. 3). Interestingly, it harbours a
glycosylation site (Asn91) close to the AP suggesting that it is sta-
bilizing the AP and consequently protects prolegumain against
proteolysis, i.e. premature activation. In contrast to caspases, the
intersubunit linker (loop L2 in caspase nomenclature) is ordered in
legumain and forms helix aII. The substrate speciﬁcity loops c341
and c381 (caspase-1 numbering) differ in size. Legumain has a
prolonged and well-structured c341-loop forming the platform for
non-primed substrate recognition. The c381-loop in legumain is
shortened to a minimum, but it harbours a glycosylation site
Asn263 (Figs. 3 and 6). This glyco-moiety on Asn263 may prove
important for substrate speciﬁcity at P5 and upwards. Interestingly,
plant legumains have a c381-loop that is comparable in length to
caspases and consistently lack the glycosylation on this loop. This
comparison suggests that the role of the c381-loop in substraterecognition is basically replaced by the glycosylation at position
263 in mammalian legumains. Moreover, legumain's S1-speciﬁcity
pocket differs from caspases. Its bipolar nature makes it speciﬁc for
Asn over Asp (Fig. 5D). Unlike caspases, mature legumain is a single
chain, monomeric enzyme. Legumain exploits an activation route
different from caspases. The death domain like fold of the LSAM
domain links it to the monomeric caspases carrying N-terminal
CARD (caspase-1, 9) or DED domains (caspase-8) [169]. Although
structures of procaspase-1 (pdb entry 3e4c) and procaspase-8 (pdb
entry 2k7z) are available, the exact position of the prodomain
relative to the catalytic domain is still not clear. Conversely, the
crystal structure of prolegumain gives a structural hint on the po-
tential position of the N-terminal prodomain in caspases, which
can be checked by biochemical data.8. Substrate speciﬁcity
8.1. P1 Asn/Asp
Legumain has a very narrow substrate speciﬁcity, cleaving
selectively after asparagine residues. Only at very acidic pH con-
ditions, aspartic acid is also tolerated [81,170,171]. This observation
was conﬁrmed in mammals and plants likewise and can be un-
derstood by the steric restraints and the zwitterionic architecture
implemented in the S1-speciﬁcity pocket (Fig. 5D). The negatively
charged hemisphere ideally stabilizes the NH2 of an asparagine side
chain, but will cause electrostatic repulsion of a charged aspartate
at pH 5.5, although it would ﬁt in size. This is contrasting the sit-
uation in caspases, where Serc347 and Glnc283 are in place of the
negatively charged residues of legumain. However, at a pH  the
pKa of aspartic acid (~3.8) the side chain becomes protonated and
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Importantly, legumain P1 substrate speciﬁcity for asparagine
does not tolerate post-translational modiﬁcations such as N-linked
glycosylation and iso-Asp formation. Likewise, asparagine deami-
dation interferes with processing as seen on the example of the
tetanus toxin C-terminal fragment TTCF [173].
8.2. P3eP2 and P10
Besides its strict speciﬁcity for Asn at P1 position, legumain is
less selective at P3eP2 and primed positions. The c341-loop serves
as a template for nonprimed substrate binding, mediated by anti-
parallel b-sheet formation of the substrate with Ser216-Tyr220 on
the bIV strand (Fig. 5D). Peptide libraries have been used to deter-
mine cleavage preferences of pig, Schistosoma and human legu-
main. As a result it turned out that Arg/Lys/His are well tolerated at
P10 whereas D/E are converted slower [174]. This observation is
consistent with kcat tuning effects that result from changes in the
local pKa of the catalytic Cys189, as discussed in the next paragraph
[13]. Residues with small side chains (G, C, N, S, A) are also well
tolerated at P10 whereas proline was not well tolerated [174].
Additionally, substrate speciﬁcity between legumains from
different species seems to differ. This can be exempliﬁed by Schis-
tosoma legumain which has an ideal cleavage sequence of
ThreAlaeAsn (P3eP2eP1) whereas the human enzyme prefers
ProeThreAsn [175]. Interestingly, plant legumain showed a pref-
erence for bulky residues at P3 position [171]. Additionally, glyco-
sylation on the 381-loop likely has a modulating effect on non-
primed substrate speciﬁcity [13].
8.3. Tuning legumain protease activity: kcat selection
“How can a cysteine protease be active at acidic pH?” is one of
the major questions when working with lysosomal cysteine pro-
teases. Deprotonation of the catalytic Cys Sg is essential to perform
a nucleophilic attack. In chymotrypsin-like serine proteases a cat-
alytic His serves as a base and abstracts the proton from the cata-
lytic Ser, enabling it to perform a nucleophilic attack [176,177].
Lysosomal cathepsins belonging to the papain-like cysteine prote-
ase family employ an analogous triad with an imidazoliume thio-
late ion pair stabilization. Additionally, the catalytic cysteine is
placed at the beginning of an a-helix; this helix cap with its positive
charge of the helix dipole further favours the thiolate state, as re-
ﬂected by a resulting pKa of 3.6 [178e180].
Such pKa tuning is not possible in caspase-like enzymes where
the catalytic His237c is ~6 Å away from the catalytic Cys285c Sg
(Fig. 5D). Therefore, His237c (His148 in legumain) cannot abstract
the Sg proton. Consequently, the deprotonation of legumain's cat-
alytic Cys189 can be expected to become the rate-limiting step at
acidic pH of the lysosome. This pH dependence is indeed exploited
by Glu190 in human legumain which implements a kcat-driven
mechanism to ﬁne-tune its substrate speciﬁcity [13]. The highly
conserved Glu190 is positioned next to the catalytic Cys189 and
leads to an increase of the local pKa of Cys189 by stabilizing the
proton at Sg (Fig. 5D). Legumain thus harbours a carboxylatee thiol
polar pair with reversed signs as compared to the imidazoliume-
thiolate ion pair found in cathepsins. In agreement with this anal-
ysis, the charge reversal mutant E190K positions a positive charge
close to the catalytic Cys189 and thereby enhances legumain's kcat
by decreasing the local pKa of Cys189. The E190Kmutation does not
alter the substrate binding afﬁnity (KM) but the turnover speed
(kcat). Substrates presenting charged residues at P10 and P20 posi-
tion may therefore regulate their own turnover speed, in agree-
ment with results from Schwarz et al. [174], as described in the
previous paragraph.8.4. ACP substrate speciﬁcity
Using peptide competition assays it could be shown that legu-
main's asparaginyl carboxypeptidase (ACP) activity is a preferential
mono-carboxy-peptidase, selectively removing one amino acid
from a protein C-terminus (Fig. 5C) [13]. As AEP, the ACP-activity
obligatory requires an Asn at P1 position. However, a free C-ter-
minus can likely be replaced by an aspartic acid at P10 position,
since the side chain of Asp resembles a C-terminus. This substitu-
tion is, for example, observed in the auto-catalytic Asn323-Asp324
cleavage site of human prolegumain. ACP's substrate preference in
P10 is thus reversed to AEP's P10 preference where Asp or Glu would
be disfavoured because of their adverse kcat effect.
9. Ligase activities
9.1. ATP-dependent ligases
In order to link two peptides via a peptide bond, the C-terminus
of one fragment needs to be activated. While a large variety of
coupling reagents such as ester and anhydride bonds are used in
synthetic chemistry, physiological activation is achieved by the
formation of energy rich bonds, in particular carboxylate phosphate
mixed anhydrides [181]. Typically, either one of two energy rich
ATP-derived intermediates is observed in vivo: aminoacyl-AMP
(aa þ ATP / aa-AMP þ PPi; aa: amino acid) and amino-
acylphosphate (aa þ ATP/ aa-Pi þ ADP). The ribosome uses the
ﬁrst intermediate to synthesize peptide bonds. In this case an
aminoacyl-AMP is transferred to a t-RNA, consequently releasing
the AMP. Thereby a stable aminoacyl-tRNA intermediate is gener-
ated [182,183]. Non-ribosomal synthetases like glutathione syn-
thase and L-amino acid a-ligase are examples for enzymes forming
peptide bonds via an aminoacylphosphate intermediate [183e186].
The schematics of ATP-dependent ligation reactions are shown in
Fig. 7A.
9.2. ATP-independent transpeptidases
Besides the classic ATP-dependent, de novo peptide bond syn-
thesis, there are also examples for ATP-independent transpeptidase
mechanisms, such as implemented in inteins and sortases. Inteins
catalyse a protein splicing reaction, i.e. the autocatalytic excision of
an internal domain (“intein”) within a protein. In themost common
situation, the central intein domain is ﬂanked at the N-terminal and
C-terminal side by the N-extein and C-extein domain, respectively.
Inteins are found in prokaryotes, eukaryotes and archaea, albeit in
varying numbers. Methanococcus jannaschii for example contains
19 inteins [187,188].
Their catalytic mechanism is essentially composed of 4 steps
and repeatedly exploits nucleophilic substitution reactions as in
serine or cysteine proteases. Therefore, suitable nucleophiles (Ser/
Cys/Thr) must be present both at the N-terminus of the intein and
of the C-extein; additionally, an Asn must be present at the intein's
C-terminus. The splicing reaction starts with the intein's Cys1/Ser1
attack of the N-terminal splice junction, converting the N-
exteineintein peptide bond into a (thio)ester intermediate (step 1).
An analogous nucleophilic attack (step 2) by the C-extein nucleo-
phile Cys þ 1/Thr þ 1/Ser þ 1 results in a branched (thio)ester in-
termediate between the N-extein and the C-extein, whereby the
intein is still connectedwith the C-extein. In a next step, (step 3) the
intein's C-terminal Asn cyclises into a succinimide, thereby
releasing the intein from the extein domains. Finally, (step 4) by an
acyl shift the (thio)ester bond between the extein domains is
converted to an amide bond, i.e. a standard peptide bond [189].
Sortases are transpeptidases present only in Gram-positive
Fig. 7. Schematics of catalytic mechanisms employed to form peptide bonds. A, In ATP-dependent protein synthesis, such as by the ribosome, energy rich ATP is used to activate a
carboxy-terminus (peptide1) by covalently attaching an AMP (A is adenosine). B, By contrast, transpeptidation reactions use a nucleophile, usually the Og of a serine or the Sg of a
cysteine, to activate a peptide bond (R is the Ca of the P10 amino acid) or the carbamoyl group of a glutamine side chain (R is a hydrogen). While inteins and sortases attack a peptide
bond and transfer a new peptide, transglutaminases attack a glutamine side chain and form an isopeptide bond with the Nz of a lysine. C, In legumain, the C-terminal carboxylic acid
of the substrate is activated by an energy rich Asu147 found in the active site. Thereby, an anhydride intermediate is generated. In either case the reaction proceeds with the
formation of a peptide bond, linking peptide 2 via its free amino group to the C-terminus of peptide 1. The nucleophile of “peptide2” could be the amino group of a peptide or the Nz
of a lysine side chain.
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tein to the peptidoglycan cell wall [190,191]. There are 4 subfamilies
sortase AeD, with sortase A being most prominent and present in
most gram-positive bacteria [192]. Their catalytic mechanism ex-
ploits a conserved Cys residue that performs a nucleophilic attack
of the substrate at the conserved LPXT-G motif (usually between T
and G). Thereby a tetrahedral intermediate is generated, leading to
the rupture of the peptide bond and the concomitant release of the
primed side product. Themechanism thusmimics that of a cysteine
protease. Importantly, the resulting thio-ester in sortases is long-
lived enough to allow the free N-terminus from a peptidoglycan
precursor (or a Lys side chain) to attack. Thereby a second tetra-
hedral thio-hemiketal intermediate is generated. Finally, the cata-
lytic Cys is released, completing the formation of the new peptide
bond and the regeneration of the enzyme [193e195]. The sche-
matics of intein- or sortase-like transpeptidation reactions are
shown in Fig. 7B.
9.3. Catalytic mechanism of legumain ligase activity
Mammalian legumains can be active both as protease and ligase,
albeit with differing pH-proﬁles [106,145]. While the protease ac-
tivity dominates at acidic pH, the ligase activity dominates at near
neutral pH. Both activities are in a pH dependent equilibrium, su-
perposing each other. For human legumain it was further shown
that the ligase activity is independent of the catalytic Cys189. Co-
valent modiﬁcation of Cys189 Sg uncoupled the ligase and protease
activities by blocking the protease but not the ligase activity. This
uncoupling was structurally translated into a rotation of the cata-
lytic Cys189 Sg away from the scissile peptide bond in the legu-
mainecystatin E complex, representing the ligase state of the
enzyme (Fig. 8B) [106]. These observations exclude sortase and
intein-like mechanisms and thus appear in marked contrast to themechanism proposed for plant legumains, as discussed below
[15,144]. The lack of a thio-ester intermediate in the ligation by
human legumain poses the question for an alternative energy
source which could activate the P10 carboxylate and thereby enable
peptide bond formation. The crystal structures of human, mouse
and also CHO legumain uncovered a conserved succinimide/
aspartimide147 (Asu147) preceding the catalytic His148 (as evi-
denced by the electron density of, for example, pdb entries 4n6o,
4noj) (Fig. 8B) [106,145,146]. Succinimides are generated from the
Asp precursor via a condensation reaction [196]. The conversion of
Asp/Asn residues to succinimide and subsequent Asp racemization
in proteins is diagnostic to the ageing of proteins and is also
important in age-related diseases like AD and cataract [197e199].
Succinimides are energy rich moieties that represent the transition
state between the conversion of an Asn to Asp via deamidation
[196]. Succinimides are labile inwater and pH sensitive, i.e. they are
easily hydrolysed at neutral pH by a hydroxide but can be stabilized
at acidic pH where OH concentration is low [200,201]. Because
they harbour energy rich bonds (like ATP) they are used as coupling
reagents [181]. The coupling of proteins via free amines onto a
biosensor chip also exploits this feature [202]. Interestingly, suc-
cinimide residues have also been found in different crystal struc-
tures, e.g. lysozyme [203] and amylomaltase. In the latter case
succinimide formation is thought to be accelerated at increasing
temperature and be indicative for increased protein stability of the
enzyme from Thermus thermophilus [204].
Prolegumain harbours an Asp147 when it leaves ribosomal
protein biosynthesis, as conﬁrmed via mass spectrometric analysis.
However, during autocatalytic activation the Asp is converted to an
aspartimide (Asu) as observed in human legumain. Asp147 is
strictly conserved throughout all legumain sequences, like the
catalytic protease triad is, but is mostly Ser, Ala or Gly in caspases
(Fig. 3). Additionally, mutagenesis studies (D147S) indicate the
Fig. 8. Interaction of cystatins with legumain. A, Crystal structure of legumain (AEP, green) in complex with human cystatin E (light blue). RCL: reactive centre loop, LEL: legumain
exosite loop. The binding site of papain-like enzymes is indicated by a red circle. B, Zoom-in view on the legumain active site. The cystatin E reactive centre loop harbours the
conserved Asn39 (blue sticks) and binds like a substrate to the AEP active site. Catalytic residues are indicated in green sticks, the cystatin E reactive centre loop in dark blue. C,
Schematic model of legumain inhibition by cystatins. Cystatins (blue) bind to legumain (green) at pH > 4. Depending on the pH environment an equilibrium between Asn39-
processed and intact/religated cystatin will be established. At acidic pH the processed variant dominates, whereas at neutral pH intact cystatin is abundant. Cleaved inhibitor
remains bound to legumain because of exosite interactions mediated by the LEL (purple).
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on these observations a mechanism of legumain ligase activity was
proposed, where Cys189 is cleaving a substrate, thereby releasing a
free C-terminus (step 1). Next, the free P1 C-terminus can attack the
proximal Asu147, resulting in an energy rich carboxylate anhydride
(step 2; Fig. 7C). Then another succinimide-intermediate is gener-
ated by the P1-Asn (step 3). The P1-Asu is ﬁnally attacked by the
free P10 N-terminus (step 4), thereby regenerating the P1 aspara-
gine. In this model, the P1 Asu formation (step 3) is optional and
depends on the structural/steric requirements of the substrate
[106].
By contrast, recent studies on plant legumain and SFTI-1 by
Bernath-Levin and colleagues suggest a sortase-like mechanism for
the transpeptidation reaction (Fig. 7B) [144]. Accordingly, the re-
action starts with the attack of the P1 Asp by C189 Sg, forming a
classical thio hemiketal intermediate. After release of the C-ter-
minal cleavage product, the thioester intermediate must be pro-
tected from premature hydrolysis. Then the primed (i.e. C-terminal)
ligase substrate binds and its P10 Gly nucleophile substitutes and
releases the catalytic cysteine [144].
Given the high sequence conservation betweenmammalian and
plant legumains, it appears possible that the aspartimide-mediated
and the thioester-mediated ligation reaction can be catalysed by
one and the same enzyme, albeit with different preferences under
different conditions, e.g., different pH optima for either reaction.9.4. Ligase substrates and speciﬁcity
Legumain ligase activity has been proven for human, mouse and
plant forms [106,145,205]. Ligase substrates identiﬁed in mammals
include (pro)legumain itself, which is capable of reverting the
Asn323-cleaved, activated form into the uncleaved zymogen form
(Table 2). Furthermore human legumain is processing and ligating
cystatin inhibitors after a conserved Asn39 residue [106]. Ligase
substrates and products known fromplants include concanavalin A,
SFTI-1 and cyclotides. In concanavalin A legumain acts as a splicing
enzyme by excising an internal propeptide and re-linking distant
parts of the protein in an inverted orientation [205]. PawS1 is the
precursor of the sunﬂower trypsin inhibitor 1 (SFTI-1), a 14 amino
acid long, cyclic, disulﬁde-bonded inhibitor. PawS1 encodes 2
mature proteins: SFTI-1 and an albumin [206]. Legumains functionhere is to excise the 14 aa SFTI-1 peptide and perform the ring-
closure reaction, in order to obtain the mature cyclic inhibitor.
Cyclotides are cyclic peptides that play important functions in plant
defence against pathogens [119]. They are structurally character-
ized by a head-to-tail cyclised backbone and 3 conserved disulﬁdes
with knotted topology. Prominent examples include the kalata-
type peptides and cyclic knottin-type peptides. Members of both
families have been identiﬁed as legumain protease/ligase sub-
strates, e.g. Oak1, the precursor of kalata B1 and MCoTI-II, the cyclic
miniprotein Momordica cochinchinensis Trypsin Inhibitor II
[122,207,208].9.4.1. P1 Asn/Asp
These substrates have in common a conserved Asn/Asp at P1
position of the protease and the ligase substrate; this speciﬁcity is
dictated by legumain's S1 site. Cleavage after the Asn/Asp is
obligatory as this generates the C-terminal free Asn/Asp that serves
as P1 residue of the ligase substrate. In case of cystatin E, mutation
of the P1-Asn39 residue to Asp completely abolished ligase activity
[106]. Both SFTI and cyclotides need processing after Asn or Asp
residues and ligation to result in a mature, cyclic peptide (Table 2).
While concanavalin A and kalata-type peptides have an Asn at P1
position of the ligase substrate, SFTI and knottins have Asp residues.
Gillon and colleagues also showed that mutating the P1-Asn to Asp
abolished cyclisation of kalata B1 [122]. This is also in agreement
with observations by Nguyen and co-workers who showed that
replacing the P1-Asn by Asp in their model peptide led to a
tremendous reduction of the ligation efﬁcacy (less than 10% in 4 h)
[15]. Additionally, Bernath-Levin and colleagues recently showed
that mutation of the P1-Asp to Asn led to a ~800-fold increase in
ligation efﬁcacy, suggesting that the Asn is in principle a better
ligase substrate [144]. However, ligation kinetics is not necessarily
optimized for a fast but rather for a speciﬁc reaction. For the
macrocyclisation of SFTI several cleavages have to occur in a
deﬁned orderwhich is guaranteed by the choice of an Asn (fast) and
Asp (slow) at P1. The authors suggest that the choice of the addi-
tional cleavages after Asn that are necessary to generate/release the
C-terminal Gly (P10), happen faster than the cleavage after Asp.
Thereby it is guaranteed that the P10 nucleophile is available and
ready to attack when the metastable P1 Asp-thioester forms, thus
minimizing futile hydrolysis events [144].
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Cystatins present Asp and Ser residues at the P10 position of the
protease/ligase substrate (Table 2). The cyclic substrates have a
glycine at P10 position (the C-terminus to be linked), in concanav-
alin A the P1-Asn is linked to a P10-Ser. Recently, Nguyen et al.
performed a systematic speciﬁcity proﬁling of butelase 1 ligase
activity, a legumain homolog from the seeds of Clitoria ternatea.
They found that at P10-position virtually every natural amino acid is
accepted except for Pro and acidic residues like Asp and Glu.
However, the P20 seems to be more critical. Here only Leu, Ile, Val,
and Cys were tolerated [15]. This is also in agreement with earlier
observations by Gillon et al. [122]. However, Bernath-Levin and
colleagues showed that mutating the P10-Gly to Ala prevented
macrocyclization in a synthetic substrate [144].
In general, cyclic peptides usually have well-deﬁned confor-
mations and are very stable molecules due to resistance to pro-
teolytic processing, particularly stable cross-linked hydrogen
bonds, further stabilization by disulﬁde bonds and lack of confor-
mational rearrangement upon binding to their target (protease)
[209,210]. They are extremely resistant even to harsh chemical
conditions like in the digestive tract [211]. These features make
them a promising scaffold for the design of orally available drugs.
10. Activity regulation
10.1. Protein inhibitors
10.1.1. Cystatins
Cystatins form a superfamily of cysteine protease inhibitors
which is further subdivided into four subfamilies: steﬁns, cystatins,
kininogens and non-inhibitory cystatins. Family 1 cystatins (steﬁns)
are mainly localized intracellularly. However, extracellular loca-
tions have also been proven [212,213]. They are potent inhibitors of
papain and papain-like enzymes with a Ki in the low nM range
[16,214]. Due to an N-terminal signal peptide, type 2 cystatins are
secreted outside the cell. Selected members of the family 2 cys-
tatins were shown to be potent legumain inhibitors with Ki values
in the low nM/pM range [167,168,215]. A conserved asparagine
(Asn39, cystatin C numbering) was proven to be important for
legumain inhibition. Asn39 is located between helix a1 and b2, on a
reactive centre loop different to the papain inhibitory site (Fig. 8A)
[167]. Although all members of the cystatin superfamily share the
conserved Asn39 essential for legumain inhibition, only selected
members of the family 2 cystatins are inhibiting legumain. These
members are cystatin C, E/M and F. Cystatin E/M is the most potent
legumain inhibitor (Ki ¼ 0.0016 nM) followed by cystatin C and F
[16,167]. The crystal structure of a legumainecystatin E complex
revealed that cystatins bind to the legumain active site canonically,
i.e. in a substrate-like manner with the Asn39 on the reactive centre
loop serving as P1 residue (Fig. 8). The inhibitor is processed like a
substrate after the Asn39. However, the cleavage products remain
bound to the enzyme because the enzymeeproduct complex is
stabilized via exosite interactions that are mediated by cystatin's
legumain exosite loop (LEL). Based on in silico docking studies and
co-migration on gel ﬁltration it seems very likely that a ternary
complex composed of a papain-like enzyme and legumain simul-
taneously binding to cystatin may form in vivo [106,167]. Cystatins
have also been identiﬁed in plants (phytocystatins) and parasites
[216e218].
10.1.2. Clitocypin/macrocypin
Clitocypinwas isolated from the fungus Clitocybe nebularis. It is a
16 kDa protein that belongs to family I48 in the MEROPS database.
Clitocypin inhibits papain-like enzymes, legumain and bromelain
[219,220]. More recently, macrocypins from Macrolepiota procerahave been identiﬁed [221]. Macrocypins are ~20% identical in
sequence to clitocypin and have been subdivided in 5 subgroups
(macrocypin 1-5), with macrocypin 1 and 3 being the only ones
inhibiting legumain. Both clitocypin and macrocypins were
expressed in E. coli as inclusion bodies and refolded. They proved to
be very stable proteins, capable of reversible unfolding. Structures
of clitocypin and macrocypin 1 have been solved and revealed that
they are Kunitz-type inhibitors. Together with mutagenesis data
the structures suggest disjunct papain and legumain reactive sites,
functionally resembling the situation of cystatins [222]. Inhibition
constants of macrocypins and clitocypin towards legumain are in
the nM range (Ki: rMcp1 3.3 nM; rMcp3 9.2 nM; rClt 21.5 nM).
10.1.3. Prodomain e reversible activation and zymogenization
By blocking access to the active site, the C-terminal prodomain
has an auto-inhibitory function. Interestingly, adding back the
isolated prodomain to the AEP-domain also reduced enzymatic
activity [159]. This effect is similar to cathepsins were isolated
propeptides also efﬁciently inhibited their matching cathepsin
in vitro [223]. Furthermore, autocatalytic processing at the Asn323
site is reversible in mammalian legumains and thereby an already
proteolytically activated enzyme can be converted back to the
latent zymogen state by auto-ligation [106,145].
10.1.4. How to prevent cleavage of protein substrates or canonical
inhibitors
Combining knowledge on known legumain inhibitors with
structural and biochemical information on legumain provides us
with new strategies for the design of even more potent legumain
inhibitors. An efﬁcient strategy to block legumain activity could for
instance be to have high afﬁnity binding of primed and non-primed
(cleavage) products together with its ligase activity, as it is
exploited by cystatins (“kcat<0”). Additionally, high afﬁnity binding
(KM) together with slow turnover (low kcat) will assist in preventing
cleavage and thereby trap the enzyme in a high afﬁnity complex.
kcat-tuning can be easily accomplished by introducing negative
charges on the P10eP20 binding sites of a potential inhibitor.
10.2. The environment is regulating legumain activity
Legumain activity is greatly inﬂuenced by its environment.
Acidic pH is essential for activation to the endopeptidase activity.
Importantly, the stability of the AEP-domain is also pH-dependent
(Figs. 2 and 9). The catalytic Cys189 must (transiently) exist as a
nucleophilic thiolate for catalysis, making it prone for “toxic”
oxidation; therefore, a reducing environment is favourable for ac-
tivity (Fig. 9). The LSAM domain has a pH-stabilizing effect on the
AEP-domain. Thereby legumain can act as a carboxypeptidase also
at higher pH values. Likewise, the legumain ligase activity is
dominant at near neutral pH. Therefore, pH is essentially deﬁning
which enzymatic legumain variant is present (Fig. 2).
10.3. Activators
10.3.1. Direct conformational stabilization
The LSAM domain functions as a direct electrostatic stabilizer of
the AEP domain by physically shielding it/protecting it from a
neutral pH environment (Fig. 9). Interestingly, recombinant
expression of the AEP-domain only did not result in protein, sug-
gesting that the LSAMdomain also functions as a folding chaperone
(unpublished data). Likewise, cystatins bind to legumain directly to
its active site. Thereby they block access to the substrate binding
sites and also stabilize the AEP domain. A legumainecystatin C
complex formed at pH 5.5 is stable at pH 6.5 and can release the
active enzyme by shifting pH back to 4.0. Binding to the inhibitor
Fig. 9. Different factors regulate legumain activity at different sites. In general, legu-
main activity, activation and conformational stability are inﬂuenced by pH, the redox
potential, glycosylation and glycosaminoglycans (GAGs). Substrate speciﬁcity and
turnover are directly regulated by substrates themselves presenting charged residues
close to the catalytic Cys189 (kcat effect); by the LSAM domain restricting access to the
primed interaction sites; by cystatins blocking substrate access; and by pH and the
local redox potential which tune the protonation state of Cys189. Furthermore an
allosteric RGD120 site encodes an integrin binding site.
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state and suggests a molecular recycling mechanism. The inhibitor
cystatin C thus acts as an agonist at extracellular pH conditions by
protecting legumain in the complex with some leaking legumain
accounting for a basal enzymatic activity. Upon internalization of
the legumainecystatin complex and subsequent re-entering of the
endo-lysosomal system, the free and active legumain will be
released from the complex. Binding of cystatin E to legumain is not
(easily) reversible at pH 4.0, therefore it might serve as an intra-
and extracellular inhibitor of legumain.
10.3.2. Allosteric stabilization by integrin binding
Legumainwas previously shown to bind to b1 integrins [64] and
to aVb3 integrin [23,88]. Furthermore, binding to the aVb3 integrin
had a pH-stabilizing effect on the isolated AEP-domain. In silico
modelling of the AEP-integrin complex suggests that the integrin
acts as an allosteric stabilizer, since the RGD motif is far off the
active site (Figs. 2B, 6 and 9) [13]. The aVb3 complex anchors
legumain at the surface of tumour associated macrophages (TAMs),
reﬂecting mechanistic analogies with lysosomal cathepsins that are
also anchored by TAMs and furthermore share a similar pH-
stability proﬁle [224e226].
10.3.3. Accelerators of activation
Analogous to procathepsins [227], the auto-catalytic activation
of legumain has been shown to be accelerated by glycosamino-
glycans. Chondroitin 4-sulphate (C4S), chondroitin 6-sulphate
(C6S), condroitin 4,6-sulphate (C4,6S), heparin, heparan sulphate
and chondroitin sulphate-derived decasaccharides were shown to
accelerate auto-activation at pH 4.0. At pH 5.0 only C4S and C4,6S
accelerated activation (Figs. 2B and 9) [228].
Proteoglycans are components of the extracellular matrix, but
also present in lysosomes, were they ﬁnally get degraded [229,230].
Acceleration of activation and a stimulating effect on enzymaticactivity of glycosaminoglycans is a common phenomenon observed
in (lysosomal) cathepsins [231]. Crystals structures of (active)
cathepsin K in complex with C4S are available and illustrate allo-
steric binding of GAGs to the enzyme [232]. Binding at 2 sites leads
to a pH-stabilization of the mature enzyme and an increase in
enzymatic activity towards collagen substrates. Furthermore, there
is evidence for direct binding of GAGs also to cathepsins S and B.
However, there is no consensus binding site in cathepsins but they
rather bind to different sites on different targets/enzymes. GAGs
seem to act in two ways: they stabilize the open conformation of
procathepsins thereby allowing activation at higher pH values, and
they turn the proenzyme into a better substrate for activation [227].
It is, therefore, tempting to speculate that the activating effects
found for legumain might be mediated by similar conformational
effects.
10.4. Low molecular weight inhibitors
Like other cysteine proteases legumain can be inhibited by
compounds reacting with the catalytic cysteine like maleimide,
iodacetamide/acetate, methyl-methanethiosulfonate [39,106,233].
Such compounds are rather unspeciﬁcally thiol-reactive and valu-
able for in vitro studies, but less so for cellular assays [234]. Notably,
legumain is not inhibited by the broad spectrum cysteine protease
inhibitors E-64, PMSF nor by the aspartate protease inhibitor
pepstatin A [235]. Consistent with its speciﬁcity for Asn but also
Asp, classic covalent caspase inhibitors like YVAD-cmk/fmk are also
potent legumain inhibitors [236]. Likewise, Asp and Asn residues
equipped with an acyloxymethyl ketone (AOMK) warhead have
also been proven to be efﬁcient inhibitors [170,237]. Given the
tendency of asparagine for deamidation via aspartimide formation,
it is often preferred to use a modiﬁed AzaAsn. The AzaAsn serves
the P1 residue of a small peptide and is additionally linked to a
reactive warhead. Commonly used warheads include hal-
omethylketones [238], epoxides and Michael acceptors. These in-
hibitors are also used in conjunction with ﬂuorescent labels for
in vivo imaging and can then be utilized as activity based probes for
imaging [239e242]. The latter two types of covalent inhibitors
were also successfully used towards Schistosoma and I. ricinus
legumains [243,244]. Interestingly, bovine legumain was also
shown to be inhibited by divalent cations like Hg2þ and Cu2þ [233],
probably due to the thiol-reactivity of these metals. Further inhi-
bition selectivity can be reached by extending peptidomimetic
frameworks by using non-natural amino acids [74].
11. Pathological functions
11.1. Legumain in and around cancer
Overexpression of legumain in cancer was ﬁrst reported in 2003
[64]. Meanwhile it has been shown that legumain is overexpressed
in the majority of human solid tumours, including breast cancer
[245], colorectal cancer [66], ovarian cancer [65], prostate cancer
[246] and gastric cancer [247]. Legumain was shown to promote
cell migration and its overexpression is associated with enhanced
tissue invasion and metastasis; it promotes tumorigenesis and
correlates with poor prognosis in different cancer types
[63e66,246,248,249].
Under cancer conditions, legumain was identiﬁed at locations
that appear incompatible with its pH-stability requirements like in
the nucleus, cytosol (gastric cancer) and extracellularly [66,75,247].
Nuclear legumain was found in colorectal cancer patients; however
its function in the nucleus is still unclear. Here, it needs to be sta-
bilized, for example by the LSAM domain, to survive the neutral pH
environment. The KRK289-X26-KRK318 motif, only present in
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main's nuclear localization route: prolegumain still stabilized by the
LSAM domain is localized to the nucleus via the bipartite KRK289-
X26-KRK318 motif, there it can act as a signalling molecule or,
alternatively, it can be proteolytically activated to ACP (stabilized by
the LSAM domain) and act as a protease. Possibly the Asn323 acti-
vated ACP (b-legumain) variant will be preferred over prolegumain
for nuclear import as in b-legumain the AP may fold back and such
end up with a spatial separation of the both KRK motifs similar to
the X10-12 linker [73]. However, the exact mechanism is still unclear.
Cytoplasmic legumain was shown to be ubiquitinated at Lys318
by TRAF6 in breast cancer patients. TRAF6 binds to the motif
A210NPRESSY217 on prolegumain [63]. Ubiquitinated prolegumain
forms a complex with HSP90a which promotes its intracellular
stability and secretion. Disrupting the interaction between prole-
gumain and TRAF6 or inhibiting HSP90a led to a reduction in
prolegumain secretion and, consequently, had a positive effect on
tumour expansion by reducing tumour metastasis. Interestingly,
overexpression of the C189S-prolegumain dead mutant failed to
promote cell migration and invasion [63]. Pro-AEP was secreted
under stress conditions, such as starvation and hydrogen peroxide
stimulation.
Legumain is expressed not only by tumour cells but also by
surrounding stromal cells and found extracellularly in the tumour
microenvironment, either associated with cell surfaces or with
matrix proteins. Because of the reduced pH of the tumour micro-
environment, legumain can be functional, at those locations [75].
Tumour-associated macrophages (TAMs) are critical modulators of
tumour development and metastasis. High levels of legumain have
been found on the surface of TAMs, on the surface of and within
tumour and stroma cells of breast cancer and colorectal cancer pa-
tients [87,250]. These diverse localizations of legumain in and
around cancer cells suggest different functions at different locations.
Interestingly, not only the proteases but also the associated in-
hibitors are altered in cancer. For example, cystatin E has been
shown to have a positive effect on the invasiveness of human
melanoma (by suppressing legumain activity). In breast cancer,
recent studies indicate that loss of the cysteine protease inhibitor
cystatin E/M leads to increased tumour growth and metastasis
[251].
11.2. Multiple sclerosis
Legumain is a key enzyme in the processing of foreign and self
antigens; thus it critically affects the development of an immune
response or tolerance, respectively. The situation can be exempli-
ﬁed by the foreign tetanus toxin and themyelin basic protein (MBP)
and their consequent presentation on the MHCII complex [114,115].
By processing the tetanus toxin legumain generates peptides for
class II MHC presentation and thus stirs a desired immune recog-
nition; by contrast, exaggerated legumain protease activity
destructs MBP peptides that were important for presentation in the
thymus, and the development of tolerance against MBP. Alterna-
tively, undue legumain ligase activity might mask MBP peptides for
presentation and tolerance induction. This destruction (or mask-
ing) is associated with multiple sclerosis (MS) [43]. Consequently,
T-cells of MS patients respond to an MBP-derived peptide. In
healthy individuals, T-cells reactive towards this peptide were
cleared already during the process of generating tolerance towards
self-proteins [252].
11.3. Legumain in Alzheimer's disease
Rather recently legumain's involvement in Alzheimer's disease
(AD) has been recognized. Active AEP was found at increased levelsand translocated to the cytoplasm of neuronal cells of AD patients
[69]. The increased legumain activity and translocation to the
cytoplasm can be explained by acid conditions in AD brains that
increase lysosomal permeability [20,91,253]. Legumain was shown
to proteolytically process tau, which is intimately related to AD
(Fig. 10) [71]. Furthermore, SET, a multifunctional protein and in-
hibitor of protein phosphatase 2A (PP2A), becomes activated upon
legumain cleavage. Thereby PP2A phosphatase activity is sup-
pressed, resulting in tau hyperphosphorylation. This in conse-
quence furthermore leads to neuroﬁbrillary tangles (NFTs) which
are composed of hyperphosphorylated tau fragments [69].
Since SET is also a DNase inhibitor, degradation of SET by
legumain will result in DNA damage in brain. However, PIKE-L can
bind and protect SET from processing by legumain [134].
Another legumain substrate involved in AD is TAR DNA-binding
protein 43 (TDP-43). TDP-43 is a nuclear protein that is involved in
RNA splicing and it is a major component in tau-negative inclusions
of frontotemporal lobar degeneration and amyotrophic lateral
sclerosis. Under such conditions, TDP-43 is translocated to the
cytoplasm where it can be phosphorylated and cleaved by legu-
main [254].
11.4. Therapeutic and diagnostic options
Because of high legumain concentrations in the tumour micro-
environment mostly bound to the surface of tumour associated
macrophages (TAM), targeting TAMs via legumain is evaluated as a
promising strategy for delivering anti-cancer drugs [250]. Nowa-
days, basically three approaches are studied: prodrugs, DNA vac-
cines and legumain inhibition.
11.4.1. Prodrugs and targeted drug delivery
Legumain-targeted prodrugs are designed as fusion of a peptide
with C-terminal (P1) Asn coupled to a chemotherapeutic reagent,
which is inactive when fused to the peptide. Legumain is the only
mammalian protease that speciﬁcally cleaves after asparagine [78].
Because legumain is only found extracellulary at high levels in the
tumour microenvironment, but sparsely otherwise [64,67,248], the
drug gets speciﬁcally activated only at its intended target cell.
Therefore, side effects are expectedly low. Examples of experimental
prodrugs include legubicin, a legumain-cleavable peptide coupled to
doxorubicin, a cytostatic drug used in chemotherapy. Legubicin was
effectively tumoricidal in murine colon carcinoma model with
reduced toxicity [64]; LEG-3, which also couples a peptide to
doxorubicin [75]; CBZ-Ala-Ala-Asn-Dox employs an analogous
peptide-doxorubicin-linkage strategy [86]; carbobenzyloxy-
alanine-alanine-asparagine-ethylenediaine-etoposide, etoposide is
the active cytostatic drug which acts by topoisomerase inhibition
and gets released upon legumain cleavage [89]; carbobenzyloxy-
alanine-alanine-asparagine-ethylenediamine-etoposide [89]; Suc-
Ala-Ala-Asn-Val-colchicine, here colchicine is the anti-mitotic drug
that inhibits microtuble formation, when released from the peptide
[255]; Ala-Ala-Asn-TAT-liposomes. The Ala-Ala-Asn recognition
peptide is linked to the cell penetrating TAT peptide via a lysine side
chain, forming an isopeptidic bond; the resulting branched TAT
peptide has strongly reduced cell penetration capacity. Only after
cleavage of the branched tripeptide by legumain, the cell pene-
trating TAT peptide is unmasked, allowing the drug-loaded lipo-
some to selectively enter the tumour cells and deliver its cell toxic
cargo [256].
Similar to the prodrug approach, nanoparticles encapsulating
doxorubicin are targeted to the tumour microenvironment via the
peptidomimetic legumain inhibitor RR-11a where they are endo-
cytosed selectively by tumour cells; consequently, doxorubicin hits
selectively the tumour cell [257]; Another variation of this
Fig. 10. Legumain is a key player in Alzheimer's disease (AD). Legumain is found translocated to the cytoplasm of neuronal cells in AD patients because of increased lysosomal
permeability accompanying cell acidosis. Here, legumain is processing Tau and SET, the inhibitor of protein phosphatase 2A (PP2A) and is thereby activating it. Consequently PP2A
phosphatase activity is suppressed, resulting in Tau hyperphosphorylation (pTau) catalysed by Tau kinases, e.g., GSK3b. This furthermore leads to the formation of neuroﬁbrillary
tangles (NFTs). NFTs are composed of truncated and hyperphosphorylated Tau. The pH environment combined with legumain ligase activity dominating at near neutral pH suggests
that legumain might cross-link NFTs by forming new intra- or intermolecular (iso)peptide bonds (red lines). Since SET is also a DNase inhibitor, degradation of SET by legumain will
result in DNA fragmentation in neurons in the brain. However, PIKE-L can bind SET and prevent its processing by legumain. Another legumain substrate involved in AD is TAR DNA-
binding protein 43 (TDP-43). TDP-43 is a nuclear protein that is involved in RNA splicing and is translocated to the cytoplasm under AD conditions where it can be phosphorylated
and cleaved.
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statin prodrug to legumain and integrin aVb3. The co-targeting led
to higher efﬁcacy in murine breast cancer models as compared to
legumain targeting only [85,88]. Similarly, the Probody-approach
captializes on the co-targeting of a therapeutic antibody in anti-
tumour treatment [258]. In the study by Desnoyers et al. the pro-
body contained a masked variant of the anti-EGFR antibody
cetuximab. Only upon cleavage by legumain, cetuximab gets acti-
vated and blocks the EGFR-pathway. The speciﬁc targeting and
activation of Probodies and prodrugs in general to the tumour
environment will reduce on-target toxicity in normal tissues.
11.4.2. DNA vaccines
DNA vaccination approaches similarly capitalize on the fact that
legumain is presented and accessible to the immune system only at
the tumour microenvironment, in particular on the surface of
tumour-associated macrophages (TAMs). By engineering artiﬁcial
poly-ubiquitin-legumain fusion vector constructs, it is possible to
ensure proteasomal degradation and class I MHC presentation, ul-
timately mounting a robust CD8þ cytotoxic T lymphocyte (CTL)
response that is directed to legumain presenting TAMs. This
concept has been tested and conﬁrmed using different variants of
legumain DNA vaccines [245,250,259]. In order to enable oral
administration of the DNA vaccine, different nanoparticle delivery
systems have been successfully employed [260].
11.4.3. Legumain imaging and its use as prognostic marker
Legumain is also considered as a negative prognostic marker
since its overexpression correlates with shorter overall survival e.g.,
in breast cancer patients [67,249]. This correlation spurs the in-
terest to monitor legumain distribution in vivo. Different imaging
strategies have been used, including quenched activity-based
probes to visualize active legumain endopeptidase [261]. Thoseprobes proved to be useful markers for primary tumour inﬂam-
mation and early stage metastatic lesions. Recently, legumain-
controlled MRI imaging techniques have been developed; legu-
main cleavage of the MRI contrast agent changed its hydropho-
bicity and could thereby promote its rotational correlation time tR
[262]. Alternative on-off switching techniques rely on legumain-
controlled disassembly of 19F MRI nanoparticles [263].
11.4.4. Inhibition/knock down of legumain to suppress tumour
progression and Alzheimer's disease
While the correlation of legumain with the hypoxic tumour
microenvironment is well established and used for targeted drug
delivery, there have been also efforts to inhibit legumain itself as a
causal target in tumour progression [239,251]. Legumain inhibition
can also be combined with other cancer targets such as aVb3
integrin in order to improve both speciﬁcity and efﬁcacy; a bispe-
ciﬁc antibody simultaneously targeting these two proteins could
inhibit the growth of primary tumours in a breast cancer mouse
model [264].
Alzheimer's disease is another area where legumain inhibition
might prove an attractive target. This notion has been fostered by
studies that link legumain directly to tauopathies, e.g., tau hyper-
phosphorylation [69,71]. Further research will be necessary to
evaluate the full potential of legumain inhibition in these disease
areas.
12. Future perspectives, outlook
12.1. Smart Legumain Activity Modulation (SLAM)
Given legumain's three orthogonal or compensatory activities
(endopeptidase, carboxypeptidase, ligase), the development of
activity-speciﬁc probes and inhibitors is especially interesting, and
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hibition of all three legumain activities may be contra-productive.
For one, activity-selective imaging tools would enable to probe
which legumain activity is found in which cellular compartment
under different (patho)physiologic conditions. Take as an example
the relevant legumain activity in cancer: Legumain's pH-stability
proﬁle suggests that its ligase activity matters in cancers where
legumain is overexpressed and translocated to the extracellular
environment, cytoplasm or the nucleus, because the ligase activity
dominates at near neutral pH. However, under such conditions the
isolated AEP-domain will not survive the neutral pH and will
therefore need further direct or indirect stabilization, e.g. via the
LSAM domain or integrin aVb3 (Figs. 2B and 9). Therefore, the sit-
uation needs further clariﬁcation. Orthogonal activity-based probes
would allow to assign distinct legumain activities to different (ex-
tra-)cellular compartments. Moreover, this assignment would form
the basis to assign legumain substrates with the relevant legumain
activity. For example, very little is currently known about human
legumain ligase substrates. However, it is conceivable that ligase
activity plays critical roles in physiological situations such as the
generation of 3d-crosslinked epitopes for class II MHC; but also in
pathological situations such as the cross-linking of NFTs or amyloid
deposits in Alzheimer's disease (Fig. 10).
How could such smart legumain activity modulators (SLAM) be
developed? Despite its complexity, there are several routes to
accomplish the SLAM development. To illustrate the principle, a
SLAM inhibitor/probe could be designed to bind to the primed (e.g.,
S20eS40) recognition sites to distinguish between endo and
carboxypeptidase; or a SLAM probe might block the thiol of the
catalytic Cys189 without blocking active site access e and thus
distinguish protease and ligase activities. In fact, MMTS is a prim-
itive variant of such a protease-speciﬁc inhibitor [106]. Since
legumain is an allosterically regulated protein, allosteric SLAMs
should also exist. The details to implement such compounds pose a
challenge, but a very rewarding one, a Grand SLAM.
12.2. Legumain web
Analogous to the caspases, legumainharbours adeath-domain like
prodomain, and several legumain isoforms were identiﬁed in plants
and ticks; additionally caspase-like functions such as in programmed
cell death were attributed to legumains in plants. These analogies
raise the question whether legumain(s) are similarly organised in a
cascade-like system. It is tempting to speculate whether there
could also be other proteases involved in such a cascade. Possibly,
there is even a death domain-like adaptor that can cross-connect
legumain via its LSAM death domain to partner proteins, similar to
ASC in the caspase-system [169]. Experimental approaches like pull
down assays will be required to address such possibilities.
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